Semaglutide
The original blockbuster GLP-1 agonist. Proven, affordable, and the gold standard starting point for weight loss.
Last updated: May 2026
Category
Weight Loss (GLP-1)
Frequency
Once weekly injection
Research
FDA Approved (Ozempic/Wegovy)Quick answer
- What is semaglutide and what does it do?
- A once-weekly GLP-1 receptor agonist (sold as Ozempic and Wegovy) that suppresses appetite and improves blood sugar. STEP trials showed an average 14.9% weight reduction over 68 weeks.
- How do you dose it?
- The FDA-approved label steps up gradually: 0.25mg weekly for the first 4 weeks, then 0.5mg, then 1mg, toward a 2.4mg maintenance dose, with the low start intended to limit early nausea. Those are the label figures, not a recommendation; the actual dose and titration pace for an individual are decided by a licensed prescriber.
- Where do you get it in Vietnam and what does it cost?
- Brand pens (Ozempic) run roughly 4.5 to 6 million VND through pharmacies like Long Châu and hospital pharmacies; research-grade vials run 1.5 to 2.5 million VND via cold-chain importers. Full Vietnam sourcing guide, or the vetted supply route.
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk and sold under the brand names Ozempic (diabetes) and Wegovy (obesity). It was the drug that sparked the global weight loss peptide revolution and remains one of the most prescribed medications in the world. For pricing and sourcing in Vietnam specifically, see our 2026 guide.
The STEP clinical trials demonstrated an average weight reduction of 14.9% over 68 weeks at the 2.4mg dose. While this is less than tirzepatide or retatrutide, semaglutide has the longest track record, the most real-world user data, and the most affordable research-grade price point. Browse all weight loss peptide options to compare.
For users new to GLP-1 peptides, or those seeking a reliable, well-understood option, Semaglutide remains an excellent first choice. It is also widely studied for cardiovascular benefits: the SELECT trial reported a 20% reduction in major adverse cardiovascular events in adults with overweight or obesity and existing cardiovascular disease.
Durability is the question most people skip. The STEP 5 trial followed users for two years and reported that weight loss held through the full period rather than rebounding once the early drop slowed, which is why semaglutide is usually described as a maintenance medication rather than a short course. For the step-by-step weight loss application and how the curve flattens over time, our semaglutide weight loss protocol walks through what the research describes, and the wider weight loss peptide hub compares it against the newer dual and triple agonists.
How It Works
Semaglutide activates GLP-1 receptors in the hypothalamus (appetite regulation center of the brain), pancreas (insulin secretion), and gastrointestinal tract (gastric emptying and satiety signaling).
By mimicking the natural GLP-1 hormone (but with a much longer half-life: 7 days vs minutes for natural GLP-1), Semaglutide produces sustained appetite suppression, improved insulin sensitivity, and reduced fasting blood glucose.
The addition of a fatty acid chain to the molecule allows it to bind to albumin in the bloodstream, dramatically extending its half-life and enabling once-weekly dosing.
Benefits
- 14.9% average weight reduction in STEP trials (up to 17.4%)
- Proven cardiovascular benefits (20% reduction in major CV events, SELECT trial)
- Extensive real-world safety data (7+ years)
- Affordable research-grade price vs Tirzepatide and Retatrutide
- Once-weekly dosing
- Improved blood sugar control
- Available in both injectable and oral forms
Dosing Described in Research and Labels
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Starting | 0.25mg | Once weekly | Weeks 1 to 4 |
| Titration 1 | 0.5mg | Once weekly | Weeks 5 to 8 |
| Titration 2 | 1mg | Once weekly | Weeks 9 to 16 |
| Titration 3 | 1.7mg | Once weekly | Weeks 17 to 20 |
| Maintenance | 2.4mg | Once weekly | Ongoing |
These figures summarise what published research and approved labels describe. They are educational, not a recommendation or a personal protocol. Any dose, schedule, or decision to use a compound belongs with a licensed prescriber.
Side Effects
Common
- ⚠Nausea (very common in first 4 to 8 weeks)
- ⚠Diarrhea or constipation
- ⚠Vomiting (usually subsides after 2 to 4 weeks)
- ⚠Decreased appetite
- ⚠Burping or acid reflux
- ⚠Injection site redness or swelling
Rare
- •Pancreatitis
- •Diabetic retinopathy changes (in existing diabetics)
- •Gallstones or cholecystitis
- •Rapid heart rate
Who Should NOT Use Semaglutide
- ✕Personal or family history of medullary thyroid carcinoma (MTC)
- ✕Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- ✕History of pancreatitis
- ✕Type 1 diabetes
- ✕Pregnancy or breastfeeding
- ✕Severe kidney or liver disease
What to Expect
Starting dose is sub-therapeutic: mainly for GI tolerance. Some mild nausea. Appetite slightly reduced.
Noticeable appetite reduction begins. Most users lose 2 to 4kg in this phase. Nausea may increase then settle.
Consistent weight loss at higher doses. Food cravings significantly reduced. The "food noise" effect is commonly reported.
Weight loss slows. Many users remain at 1mg or 1.7mg as maintenance. Some switch to Tirzepatide for additional results.
Notes from Ho Chi Minh City
Semaglutide is the GLP-1 most HCMC expats end up on first, partly because Ozempic and Wegovy are sometimes available through Long Châu and the Vinmec Central Park pharmacy in Binh Thanh at brand pricing of roughly 4.5 to 6 million VND per pen, less of a markup than people expect. The food-noise reduction is the under-discussed part of the mechanism, and it is the reason banh mi vendors on Hai Ba Trung stop registering a few weeks in. The climate-specific caveat is dehydration: in HCMC heat, dropping water intake makes GLP-1 constipation arrive fast. The approved label starts low and titrates upward on a set schedule, and the month-four plateau is well documented, but the actual dose and titration path are decisions for a licensed prescriber.
Sourcing in Vietnam
Semaglutide is available in Vietnam in two forms: brand pens (Ozempic, Wegovy, Rybelsus) at retail pharmacies including Long Châu and hospital pharmacies (4.5 to 6 million VND per Ozempic pen), and research-grade vials through cold-chain importers (1.5 to 2.5 million VND per 5mg vial). Brand pens require a prescription. See the Semaglutide Vietnam 2026 guide for full sourcing comparison.
FAQ
Q: What is the difference between Ozempic and research Semaglutide?
A: The active molecule is identical. Ozempic is manufactured to pharmaceutical standards with strict quality controls and comes in a pre-filled pen. Research-grade Semaglutide is lyophilized powder that requires reconstitution. Quality varies heavily by supplier, always verify COA. See the full Ozempic vs research-grade comparison for Vietnam buyers.
Q: Should I start with Semaglutide or Tirzepatide?
A: Semaglutide is a good starting choice if you want maximum safety data and the most affordable price. Tirzepatide produces ~50% more weight loss and has better GI tolerability. Both are excellent options.
Q: How long does reconstituted Semaglutide last?
A: Reconstituted Semaglutide stored in a refrigerator (2 to 8°C) is generally stable for 4 to 6 weeks. Always check your specific COA for storage recommendations.
Q: Can I use Semaglutide long-term?
A: Semaglutide is safe for long-term use based on clinical trial data of up to 4 years. Many users treat it as a maintenance medication indefinitely, similar to blood pressure medication.
Where to Get Semaglutide in Vietnam
For Vietnam-specific sourcing routes, hospital availability, pricing breakdowns, and supplier red flags, read the full guide. For the legal status of semaglutide in Vietnam, see the legality guide. Or browse the community-verified supplier list.
Related Peptides
Related Guides
Research & Sources
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial) · Wilding JPH, Batterham RL, Calanna S, et al. · New England Journal of Medicine (2021) PMID: 33567185
STEP 1 randomized trial showing 14.9% mean weight loss at 68 weeks on semaglutide 2.4mg weekly.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial) · Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · New England Journal of Medicine (2023) PMID: 37952131
SELECT trial demonstrating 20% reduction in major adverse cardiovascular events.
- Liraglutide and Semaglutide: Pharmacokinetics, Pharmacodynamics, and Clinical Implications · Knudsen LB, Lau J · Frontiers in Endocrinology (2019) PMID: 31031741
Pharmacology review covering the structural modifications enabling once-weekly dosing.
- Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 trial) · Garvey WT, Batterham RL, Bhatta M, et al. · Nature Medicine (2022) PMID: 36216945
STEP 5 long-term efficacy data showing weight maintenance through year 2.
Important Disclaimer
Educational content only. Not medical advice. Peptides discussed on this page are not approved by Vietnam’s Ministry of Health (Bộ Y Tế) or the Drug Administration of Vietnam (DAV) for the indications described. Research peptides are not stocked at Long Châu, Pharmacity, or any retail pharmacy in Vietnam. Consult a licensed physician before any use.